Piper Jaffray Upgrades Acadia Pharmaceuticals (ACAD) to Overweight
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- Wall St mixed as Middle East tensions eclipse tech strength
- L3Harris CEO steps down amid conduct review, shares drop
- Reddit leads social media platforms in revenue growth per user
- Northland Upgrades Astera Labs (ALAB) to Outperform, 'Right Time, Customers, and Products'
- H.C. Wainwright Reiterates Buy Rating on Soluna (SLNH)
Acadia Pharmaceuticals (ACAD) Sees Profit-Taking after Major Run-Up
April 12, 2013 9:58 AM EDTAfter surging 64 percent Thursday on news the company plans to file pimavanserin in Parkinson's disease psychosis in late 2014 without conducting the confirmatory 021 pivotal trial, shares of Acadia Pharmaceuticals, Inc. (NASDAQ: ACAD) are seeing profit taking today.
Shares were down 7% at last check, but off the lows.... More
Jefferies Raises Acadia Pharmaceuticals (ACAD) PT to $18 on Pimavanserin Win
April 12, 2013 7:11 AM EDTJefferies boosted its price target on Acadia Pharmaceuticals (NASDAQ: ACAD) from $13 to $18 after the company announced Thursday that it intends to file for pimavanserin in Parkinsons disease psychosis in late 2014 without conducting the confirmatory 021 pivotal trial.
"We believe this is a major... More
Needham & Company Boosts PT on Acadia Pharmaceuticals (ACAD) by 78%
April 11, 2013 11:02 AM EDTNeedham & Company analyst Alan Carr boosted his price target on Acadia Pharmaceuticals (NASDAQ: ACAD) from $9 to $16 it was announced this morning that only one successful Phase 3 trial of pimavanserin in Parkinson Disease Psychosis (PDP) will be needed for an NDA filing.
"We... More
Acadia Pharmaceuticals (ACAD) Surges as FDA Says Data Supports NDA Filing
April 11, 2013 7:21 AM EDTAcadia Pharmaceuticals, Inc. (NASDAQ: ACAD) is surging in pre-open action after the company announced that the FDA has agreed that the data from the pivotal Phase III -020 study, together with supportive data from other studies with pimavanserin, are sufficient to support the filing of a New Drug Application (NDA) for the treatment of Parkinsons disease psychosis (PDP).
As a result, ACADIA... More
